Table 6.

Drug content of formulations after stability studies

Storage condition 30 ± 2°C/65 ± 5% RH	Drug Content (%) of formulations
	Carvedilol	0.2% Chitosan hydrosols	0.4% Chitosan chlorhydrate hydrosols	0.2% chitosan solid dispersions	0.8% chitosan chlorhydrate solid dispersions	0.4% Chitosan Co-grinding	0.4% Chitosan chlorhydrate Co-grinding
Time 0 days	99.56 ± 1.16	98.77 ± 1.31	98.19 ± 2.13	99.66 ± 1.24	98.17 ± 1.14	99.46 ± 1.11	98.86 ± 1.15
Time 90 days	99.46 ± 1.38	98.67 ± 1.44	98.09 ± 2.34	99.76 ± 1.32	98.67 ± 1.43	99.27 ± 1.12	98.66 ± 1.34
Time 180 days	99.26 ± 1.10	98.47 ± 1.22	97.69 ± 2.01	99.16 ± 1.16	98.97 ± 1.25	99.29 ± 1.14	99.10 ± 1.17